Bristol-Myers Squibb: Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell Lung Cancer in Patients with Tumor Cell PD-L1...
Recommendation based on Phase 3 CheckMate -77T trial showing significant event-free survival improvement when compared to neoadjuvant chemotherapy and placebo followed by surgery and adjuvant plac...
Read full article »
Bristol Myers Squibb is a New Jersey-based biopharmaceutical company that discovers, develops and commercializes medicines for patients with serious diseases.
Read more